JLABS (Johnson & Johnson)

JLABS (Johnson & Johnson)
Name	JLABS
Industry	Biotechnology incubator
Founded	2012
Founder	Johnson & Johnson
Headquarters	South San Francisco, California
Area served	Global
Parent	Johnson & Johnson Innovation

JLABS (Johnson & Johnson) JLABS is a global life sciences incubator network operated by Johnson & Johnson Innovation that provides laboratory space, mentorship, and access to capital for startups in biotechnology, pharmaceuticals, medical devices, and digital health. The network aims to accelerate translational research by linking entrepreneurs with experts from Johnson & Johnson, venture capital firms such as Sequoia Capital and Kleiner Perkins, and academic institutions including Harvard University and Stanford University. JLABS sites are located in major innovation hubs and collaborate with public institutions like NIH and private organizations including Bill & Melinda Gates Foundation and Wellcome Trust.

Overview

JLABS functions as a non-dilutive incubator model offering modular wet labs, office space, and shared equipment to resident companies while fostering connections to corporate development teams from Johnson & Johnson, strategic partners such as Pfizer, Roche, and Novartis, and investors including Andreessen Horowitz, Third Rock Ventures, and ARCH Venture Partners. The program emphasizes translational milestones that align with regulatory pathways overseen by agencies like the FDA and European Medicines Agency, and it integrates resources from research centers including MIT and University of California, San Francisco. JLABS has been cited in analyses alongside accelerators such as Y Combinator, incubators like Cambridge Innovation Center, and innovation initiatives from Google X and Microsoft Research.

History and Development

JLABS was launched in 2012 by Johnson & Johnson Innovation as part of a corporate strategy seen in contemporaneous efforts by GlaxoSmithKline and AstraZeneca to engage external innovation. Early development involved partnerships with academic spinouts from Massachusetts Institute of Technology, California Institute of Technology, and University of Cambridge. Expansion milestones included openings in ecosystems represented by San Francisco Bay Area, Boston, and New York City, mirroring trends exemplified by entities such as Genentech and Biogen. Over time JLABS adapted to challenges highlighted during the COVID-19 pandemic by collaborating with organizations like BARDA and accelerating programs similar to efforts by Moderna and BioNTech.

Facilities and Global Network

JLABS operates multiple campuses across North America, Europe, and Asia, with sites in locales comparable to major hubs such as Toronto, London, Shanghai, Beijing, San Diego, and Leiden. Facilities provide biosafety infrastructure often required for work that would interface with standards set by CDC and WHO. The network complements other regional incubators including MaRS Discovery District and Biocity and is co-located near institutions like Johns Hopkins University and Imperial College London to facilitate talent flow from academic centers such as University of Toronto and Erasmus University Rotterdam.

Programs and Services

Programs at JLABS include mentorship from scientific leaders formerly affiliated with National Institutes of Health and industry executives from Merck and Eli Lilly, business development support similar to services at Plug and Play Tech Center, and curated investor showcases akin to BIO International Convention pitch sessions. Services extend to regulatory strategy workshops referencing guidance from the FDA and EMA, access to specialized equipment comparable to offerings at Broad Institute, and connections to contract research organizations like Charles River Laboratories and Covance. JLABS also runs themed incubator initiatives focused on fields linked to projects from GAVI, CEPI, and academic consortia such as Human Genome Project collaborators.

Partnerships and Funding

JLABS leverages strategic partnerships with corporate partners including Johnson & Johnson, co-investors like Novo Holdings, foundations such as Wellcome Trust and Bill & Melinda Gates Foundation, and government programs like NIH grants and EU Horizon 2020. Resident companies retain independence while accessing deal flow discussions with corporate development teams from Johnson & Johnson Innovation and potential acquirers like Sanofi and Bayer. Funding pathways for alumni have included venture rounds led by firms such as Flagship Pioneering and Lux Capital, as well as non-dilutive awards modeled after SBIR grants and philanthropic prize programs like the XPRIZE.

Impact and Criticism

Impact assessments cite JLABS for accelerating translational projects that later partnered with firms such as AbbVie and Gilead Sciences, and for supporting startups that advanced into clinical trials registered in databases like ClinicalTrials.gov. Critics and analysts from outlets including The Wall Street Journal and Financial Times note tensions between corporate-linked incubators and startup independence, comparing debates around JLABS to critiques leveled at industry initiatives by GlaxoSmithKline and Pfizer. Other concerns reference accessibility and diversity challenges similar to those reported at accelerators like Techstars and 500 Startups, and questions about long-term outcomes echo evaluations by think tanks such as Brookings Institution and RAND Corporation.

Category:Biotechnology incubators Category:Johnson & Johnson